LCM
EDSA icon

Lynwood Capital Management’s Edesa Biotech EDSA Stock Holding History

Lynwood Capital Management’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-41,071
Closed -$262K – 115
2023
Q1 		$262K Buy
41,071
+23,665
+136% +$247K 0.24% 78
2022
Q4 		$264K Buy
+17,406
New +$130K 0.32% 72

Other funds holding EDSA

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $62.3B AUM 44.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Lynwood Capital Management's EDSA Position: Q2 2023 in Review

Lynwood Capital Management sold out of Edesa Biotech (EDSA) in Q2 2023, closing a stake of 41,071 shares — an estimated $262K sold.

Lynwood Capital Management first reported a position in EDSA in Q4 2022 and held it in 2 quarters. The position peaked at $264K in Q4 2022. 22 funds tracked by Wall St. Rank hold EDSA as of Q2 2023.

  • Lynwood Capital Management reported no remaining Edesa Biotech position as of Q2 2023 after selling out during the quarter.
  • Lynwood Capital Management sold 41,071 Edesa Biotech shares in Q2 2023, an estimated $262K.
  • Lynwood Capital Management first reported a position in Edesa Biotech in Q4 2022 and held it in 2 quarters.
  • Lynwood Capital Management's Edesa Biotech position peaked at $264K in Q4 2022.
  • 22 funds tracked by Wall St. Rank held Edesa Biotech as of Q2 2023.

Based on Lynwood Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.